SDxLabs

Just like Pi, our research possibilities are endless when developing methods for the detection and understanding of complex medical conditions. Visit our website to learn more about how we hope to make an impact with noninvasive screening solutions.

Happy New Year from Signature!

Wishing you and your family a happy Thanksgiving!

1p36 deletion syndrome is a type of microdeletion caused by a missing piece of chromosome 1. Children with 1p36 deletion syndrome have intellectual disabilities, and most have heart defects and weak muscle tone.

Learn more about this condition and others available for screening with Prenactive™ Noninvasive Prenatal Screening Plus: https://sdx-labs.com/noninvasive-prenatal-screening-2/

Happy Veterans Day! Thank you to all of our United States Veterans for their bravery and service to this country.

Noninvasive Prenatal Screening (NIPS) can be done as early as 10 weeks of pregnancy and remains available through delivery. For answers to more FAQs about Prenactive™ NIPS, visit https://sdx-labs.com/understanding-noninvasive-prenatal-screening-nips/

The microdeletion syndrome caused by a deletion at 15q11.2 depends on if the deletion is on the chromosome 15 inherited from the baby’s mother or father. If the deletion is on the 15 inherited from the baby’s father, the baby has Prader-Willi syndrome.

If the deletion is on the 15 inherited from the baby’s mother, the baby has Angelman syndrome. Both Angelman syndrome and Prader-Willi syndrome can be due to other types of chromosomal changes, not just a 15q11.2 deletion.

Learn more about these conditions and others available for screening with Prenactive™ Noninvasive Prenatal Screening Plus: https://sdx-labs.com/noninvasive-prenatal-screening-2/

Noninvasive Prenatal Screening (NIPS) can detect the s*x of the baby when the provider orders testing for s*x chromosome aneuploidies in singleton (one baby) pregnancies. In twin pregnancies, NIPS only can only detect if at least 1 baby is male or if neither are male.

For answers to more FAQs about Prenactive™ NIPS, visit https://sdx-labs.com/understanding-noninvasive-prenatal-screening-nips/

Down Syndrome Awareness Month (DSAM) is observed every October to promote advocacy, break down barriers, and celebrate the many abilities of our loved ones with Down syndrome. Learn more about DSAM from the National Down Syndrome Society: https://ndss.org/down-syndrome-awareness-month

Clinical drug development has been on the rise in recent years, due in part to an industry-wide adoption of new technology-driven productivity enablers and a shift in research focus from COVID-19. As we continue to see heightened activity across the pharmaceutical R&D landscape, genetic testing for determining cohort inclusion plays an important role in moving clinical trials forward.

Learn about our clinical phenotyping services for drug trials: https://sdx-labs.com/pgx-clinical-trials/

22q11.2 deletion syndrome, also called DiGeorge syndrome or Velo-Cardio-Facial syndrome (VCFS), is caused by a missing piece of chromosome number 22. The majority of children with this disorder have heart defects, immune system problems, specific facial features, and learning difficulties.

Learn more about 22q11.2 deletion syndrome and other conditions screened for with Prenactive™ Noninvasive Prenatal Screening Plus: https://sdx-labs.com/noninvasive-prenatal-screening-2/